With regard to the ND AML cohort, in patients with IDH1/2 wild type and RUNX1 wild type, the FLT3mut group achieved a superior response (CRc) than the FLT3wt group (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.0–9.4; p = 0.044; OR, 3.5; 95% CI: 1.1–11.0; p = 0.033; Figure S1A, respectively). This evidence concerns the gene IDH1 and acute myeloid leukemia.